CBLB and neoplasm: Our results in organoids from TNBC and colon cancer, two tumor types which can suppress immune responses (52, 53), suggest that Notch1 reactivation via Cbl-b inhibition could be a promising strategy to sensitize “cold” immunosuppressive tumors to cancer immunotherapy.